Cambridge Antibody acquires Enzon oncology product

By Elaine Rigoli

Tampa, Fla., July 27 - Cambridge Antibody Technology has acquired from Enzon Pharmaceuticals, Inc. product candidate SS1P (renamed CAT-5001).

The company said it will start a clinical study in early 2007 exploring dosing of CAT-5001 in combination with cytotoxic chemotherapy.

"Following the acquisition of CAT-3888 and CAT-8015 in October last year, the acquisition of CAT-5001 is a further step in enhancing our pipeline and presence in oncology," senior vice president of development Patrick Round stated in a news release.

Enzon Pharmaceuticals is based in Bridgewater, N.J.

Cambridge Antibody is a biopharmaceutical company based near Cambridge, England.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.